{"id":"epsilon-aminocaproic-acid-administered","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombosis / thromboembolic events"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myopathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This antifibrinolytic agent works by competitively inhibiting the binding of plasminogen and plasmin to fibrin, which prevents the breakdown of blood clots. By stabilizing fibrin clots and reducing fibrinolysis, it decreases bleeding in conditions characterized by excessive fibrinolytic activity, such as during or after surgical procedures or in certain bleeding disorders.","oneSentence":"Epsilon-aminocaproic acid inhibits fibrinolysis by blocking plasminogen activation and plasmin activity, thereby reducing excessive bleeding.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:23.487Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention and treatment of excessive bleeding associated with fibrinolysis"},{"name":"Perioperative bleeding reduction in surgical patients"}]},"trialDetails":[{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":"Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children","enrollment":5000},{"nctId":"NCT06493227","phase":"NA","title":"Extended Perioperative Administration of Fibrinolysis Inhibitors After Cardiac Surgery","status":"RECRUITING","sponsor":"Saint Petersburg State University, Russia","startDate":"2024-08-01","conditions":"Thoracic Surgery, Heart Diseases, Fibrinolysis Shutdown","enrollment":1373},{"nctId":"NCT01431326","phase":"","title":"Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care","status":"COMPLETED","sponsor":"Daniel Benjamin","startDate":"2011-11","conditions":"Adenovirus, Anesthesia, Anxiety","enrollment":3520},{"nctId":"NCT02074436","phase":"PHASE2","title":"PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)","status":"TERMINATED","sponsor":"Emory University","startDate":"2014-05-23","conditions":"Hematological Malignancies, Thrombocytopenia","enrollment":29},{"nctId":"NCT04187014","phase":"PHASE2","title":"Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss After Total Hip Replacement","status":"COMPLETED","sponsor":"Carlos A Acosta-Olivo","startDate":"2020-02-06","conditions":"Blood Loss, Surgical","enrollment":90},{"nctId":"NCT02655653","phase":"PHASE3","title":"Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2008-10","conditions":"Bleeding","enrollment":114},{"nctId":"NCT03365999","phase":"PHASE2","title":"Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement.","status":"COMPLETED","sponsor":"Universidad Autonoma de Nuevo Leon","startDate":"2017-10-15","conditions":"Knee Osteoarthritis, Blood Clot, Transfusion Related Complication","enrollment":92},{"nctId":"NCT02030821","phase":"PHASE4","title":"TXA vs. Amicar in Total Knee and Hip Arthroplasty","status":"COMPLETED","sponsor":"Duke University","startDate":"2015-01","conditions":"Blood Loss, Hip Arthritis, Knee Arthritis","enrollment":246},{"nctId":"NCT01981863","phase":"PHASE4","title":"Fibrinolysis Before Cardiopulmonary Bypass?","status":"COMPLETED","sponsor":"Stanford University","startDate":"2013-07","conditions":"Pathologic Fibrinolysis","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Epsilon-aminocaproic acid administered","genericName":"Epsilon-aminocaproic acid administered","companyName":"Montefiore Medical Center","companyId":"montefiore-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epsilon-aminocaproic acid inhibits fibrinolysis by blocking plasminogen activation and plasmin activity, thereby reducing excessive bleeding. Used for Prevention and treatment of excessive bleeding associated with fibrinolysis, Perioperative bleeding reduction in surgical patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}